Error loading player: No playable sources found

4280

IBD Adverse Events Related to Therapy: Focus on Small Molecules

Date
May 20, 2024

SOCIETY: AGA Small molecules are a new exicting therapeutic class in IBD that may have potential safety signals which have not been well described in the real world. This session examines the role of small molecules with regard to pregnancy outcomes, cardiovascular events, thromboembolic risk, and cancer. The effect of other therapies on IBD, including GLP1 agonists and PPI's are also examined.

Moderators

Speaker Image for Berkeley Limketkai
University of California Los Angeles
Speaker Image for Christina Ha
Mayo Clinic Arizona

Related Products

Thumbnail for Epi II: Best of Observational Studies in IBD
Epi II: Best of Observational Studies in IBD
SOCIETY: AGA This session highlights the best of the best observational studies in IBD for DDW 2024 and provides clinical relevant and novel insights across the age and clinical spectrum, including wound healing after C-section…
Thumbnail for IBD Controlled Trials II
IBD Controlled Trials II
SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented…
Thumbnail for Uncontrolled Therapeutic Observations in IBD
Uncontrolled Therapeutic Observations in IBD
SOCIETY: AGA In this session, several clinically relevant presentations will put the attendee at the cutting edge of research and clinical care, with regard to stem cells for perinal fistulas, biologic de-escalation, subcutaneous biologics, and use of small molecules in microscopic colitis
Thumbnail for IBD Diagnosis. Monitoring, and Prediction of Complications
IBD Diagnosis. Monitoring, and Prediction of Complications
SOCIETY: AGA This session highlights the latest research on novel prediction models in IBD as well as the role of the fecal microbiome and imaging in IBD…